The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.
 
Cristina P. Rodriguez
Consulting or Advisory Role - Abbvie (I); ADC Therapeutics (I); AstraZeneca (I); beigene (I); Coherus Biosciences; Incyte (I); Karyopharm Therapeutics (I); Kite, a Gilead company (I); Millenium Pharamceuticals (I); Millenium Pharamceuticals (I)
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Denovo Biopharma (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst)
 
Vicky Wu
No Relationships to Disclose
 
Kevin Ng
No Relationships to Disclose
 
Jenna M. Voutsinas
No Relationships to Disclose
 
Ariana Dumenigo-Jimenez
No Relationships to Disclose
 
Jonathan R. Fromm
No Relationships to Disclose
 
Renato G. Martins
Honoraria - Sanofi
Research Funding - Eisai (Inst); Genentech (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Keith D. Eaton
Research Funding - Mirati Therapeutics (Inst)
 
Rafael Santana-Davila
Consulting or Advisory Role - AstraZeneca; EMD Serono; Mirati Therapeutics
Research Funding - ALX Oncology (Inst); BeyondSpring Pharmaceuticals (Inst); Genentech (Inst); ISA Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
 
Christina S Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Guardant Health; Janssen; Pfizer; Regeneron; Silverback Therapeutics; Takeda; Turning Point Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Spectrum Pharmaceuticals (Inst); TP Therapeutics (Inst)
 
Sylvia Lee
Research Funding - Bristol-Meyers Squibb (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); PACT Pharma (Inst); SeaGen (Inst); Tmunity Therapeutics, Inc. (Inst)
 
Diane Tseng
Stock and Other Ownership Interests - Forty Seven
Patents, Royalties, Other Intellectual Property - Use of Anti-CD47 Agents to Enhance Immunization. Provisional Application to U.S. Patent and Trademark Office.
 
Neal D. Futran
Consulting or Advisory Role - Stryker
 
Brittany Barber
No Relationships to Disclose
 
Emily Marchiano
No Relationships to Disclose
 
Jeffrey Houlton
No Relationships to Disclose
 
George E. Laramore
No Relationships to Disclose
 
Jay Justin Liao
No Relationships to Disclose
 
Simon S. Lo
Research Funding - Elekta (Inst)
 
Upendra Parvathaneni
No Relationships to Disclose